Cryptosporidiosis - Pipeline Review, H2 2015

Published: Dec, 2015 | Pages: 35 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Cryptosporidiosis - Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Cryptosporidiosis - Pipeline Review, H2 2015', provides an overview of the Cryptosporidiosis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Cryptosporidiosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cryptosporidiosis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Cryptosporidiosis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Cryptosporidiosis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Cryptosporidiosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Cryptosporidiosis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons To Buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Cryptosporidiosis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Cryptosporidiosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Cryptosporidiosis Overview 6
Therapeutics Development 7
Pipeline Products for Cryptosporidiosis - Overview 7
Pipeline Products for Cryptosporidiosis - Comparative Analysis 8
Cryptosporidiosis - Therapeutics under Development by Companies 9
Cryptosporidiosis - Therapeutics under Investigation by Universities/Institutes 10
Cryptosporidiosis - Pipeline Products Glance 11
Early Stage Products 11
Cryptosporidiosis - Products under Development by Companies 12
Cryptosporidiosis - Products under Investigation by Universities/Institutes 13
Cryptosporidiosis - Companies Involved in Therapeutics Development 14
ioGenetics, Inc. 14
Romark Laboratories, L.C. 15
Cryptosporidiosis - Therapeutics Assessment 16
Assessment by Monotherapy Products 16
Assessment by Target 17
Assessment by Mechanism of Action 19
Assessment by Route of Administration 21
Assessment by Molecule Type 22
Drug Profiles 24
cryptosporidiosis (divalent) vaccine - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
cryptosporidiosis vaccine - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
DBAF-201 - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
P-131 - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
RM-5038 - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Small Molecules for Cryptosporidiosis - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Small Molecules to Inhibit DHFR for Infectious Diseases - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Small Molecules to Inhibit IMPDH for Cryptosporidiosis - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Cryptosporidiosis - Dormant Projects 33
Appendix 34
Methodology 34
Coverage 34
Secondary Research 34
Primary Research 34
Expert Panel Validation 34
Contact Us 34
Disclaimer 35

List of Tables

Number of Products under Development for Cryptosporidiosis, H2 2015 7
Number of Products under Development for Cryptosporidiosis - Comparative Analysis, H2 2015 8
Number of Products under Development by Companies, H2 2015 9
Number of Products under Investigation by Universities/Institutes, H2 2015 10
Products under Development by Companies, H2 2015 12
Products under Investigation by Universities/Institutes, H2 2015 13
Cryptosporidiosis - Pipeline by ioGenetics, Inc., H2 2015 14
Cryptosporidiosis - Pipeline by Romark Laboratories, L.C., H2 2015 15
Assessment by Monotherapy Products, H2 2015 16
Number of Products by Stage and Target, H2 2015 18
Number of Products by Stage and Mechanism of Action, H2 2015 20
Number of Products by Stage and Route of Administration, H2 2015 21
Number of Products by Stage and Molecule Type, H2 2015 23
Cryptosporidiosis - Dormant Projects, H2 2015 33